MTSR - Metsera, Inc.
About Metsera, Inc. (https://metsera.com)
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Christopher Whitten Bernard | Co-Founder, President, Chief Executive Officer & Director | 1984 | $763,182 USD |
| Brian Hubbard | Chief Scientific Officer | 1973 | $582,969 USD |
| Gbolahan Amusa Benz | Executive Vice President of Strategic Finance & Investor Relations | 1974 | $496,798 USD |
| Christopher J. Visioli | Co-Founder, Chief Financial Officer & Chief Business Officer | 1976 | $292,308 USD |
| Daniel Hoey | Chief Technical Operations Officer | 1967 | – |
| Melissa Enbar | Chief Human Resources Officer | – | – |
| Michael Donovan | Chief Design Officer | – | – |
| Nancye Green | Chief Experience Officer | – | – |
| Paul L. Berns | Co-Founder & Lead Independent Director | 1967 | – |
| Steven Marso | Chief Medical Officer | 1968 | – |